Press releases

6 September, 2018

Regulatory

NeuroVive receives positive FDA feedback on its NeuroSTAT TBI development plan

Lund, Sweden, 6 September 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced positive U.S. Food and Drug Administration (FDA) feedback on its NeuroSTAT clinical d ...

28 August, 2018

NeuroVive’s NVP015 program will be accelerated through award of major research grant to Children’s Hospital of Philadelphia

Lund, Sweden, 28 August, 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that scientists at the company’s research partner the Children’s Hospital of Philadelph ...

21 August, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – June 2018

NeuroVive out-licenses targeted LHON therapy to BridgeBio

6 July, 2018

NeuroVive’s genetic mitochondrial disease drug candidate KL1333 mechanism of action published in scientific journal

Lund, Sweden and Seoul, Korea, 6 July 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...

28 June, 2018

NeuroVive’s TBI project NeuroSTAT experimental efficacy data published in scientific journal

Lund, Sweden, 28 June 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced that the traumatic brain injury (TBI) experimental study of NeuroSTAT performed at Univers ...

18 June, 2018

Regulatory

NeuroVive out-licenses targeted LHON therapy to BridgeBio Pharma’s new subsidiary Fortify Therapeutics

Lund, Sweden and Palo Alto, Calif., June 18, 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and BridgeBio Pharma today jointly announced that BridgeBio has entered into an ex ...

31 May, 2018

Regulatory

Amended number of shares and votes in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 31 May 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF), the mitochondrial medicine company, today announced an increase of the number of shares and votes in Neur ...

29 May, 2018

Regulatory

Information regarding trading of warrants issued by NeuroVive

THIS DOCUMENT IS NOT TO BE DISTRIBUTED, DIRECTLY OR INDIRECTLY, IN OR INTO THE US, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEELAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA OR IN ANY OTHER JURISDICTION W ...

22 May, 2018

Regulatory

NeuroVive Pharmaceutical AB Interim report January – March 2018

Successful rights issue

21 May, 2018

Regulatory

NeuroVive and Yungjin reports positive KL1333 phase I clinical study results paving the way for further clinical development

Lund, Sweden and Seoul, Korea, 21 May 2018 – NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) today jointly an ...

2 May, 2018

NeuroVive initiates collaboration with leading US TBI research organization

Lund, Sweden, 2 May 2018, NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced a partnership with TRACK-TBI, a network of US-based world-leading TBI clinicians and researc ...

27 April, 2018

Regulatory

Amendment: Resolutions from Annual General Meeting in NeuroVive Pharmaceutical AB (publ)

Lund, Sweden, 27 April 2018 - NeuroVive Pharmaceutical AB (Nasdaq Stockholm: NVP, OTCQX: NEVPF) (“NeuroVive”) today on 27 April 2018 held its Annual General Meeting (AGM). A summary of the resolutions ...